TKM Share Price

Open 22.42 Change Price %
High 23.42 1 Day 0.52 2.32
Low 21.56 1 Week 0.00 0.00
Close 22.97 1 Month 0.00 0.00
Volume 124457 1 Year 0.00 0.00
52 Week High 44.06
52 Week Low 27.25
TKM Important Levels
Resistance 2 24.69
Resistance 1 23.98
Pivot 22.65
Support 1 21.96
Support 2 21.25
TSE Canada Most Active Stocks
CQE 0.26 0.00%
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
YRI 4.01 -0.50%
TBE 0.03 0.00%
BTO 3.26 -0.31%
BTO 3.26 -0.31%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
GEN 0.40 17.65%
GEN 0.40 17.65%
CET 0.48 17.07%
CET 0.48 17.07%
CUM 0.90 13.92%
CUM 0.90 13.92%
More..
TSE Canada Top Losers Stocks
MM 0.06 -25.00%
MM 0.06 -25.00%
GBV 0.46 -24.59%
DNT 0.10 -9.09%
BLU 0.22 -8.33%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
GPR 1.93 -6.31%
GPR 1.93 -6.31%
DA-A 0.17 -5.56%
More..

Tekmira Pharmaceuticals Corp (TSE: TKM)

TKM Technical Analysis 1.5
As on 3rd Mar 2015 TKM Share Price closed @ 22.97 and we RECOMMEND Buy for LONG-TERM with Stoploss of 19.30 & Sell for SHORT-TERM with Stoploss of 24.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
TKM Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TKM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tekmirapharm.com
TKM Address
TKM
100-8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Canada
Phone: 604-419-3200
Fax: 604-419-3201
Interactive Technical Analysis Chart Tekmira Pharmaceuticals Corp ( TKM TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tekmira Pharmaceuticals Corp
TKM Business Profile
Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.